Logo image of NAUT

NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:NAUT - US63909J1088 - Common Stock

1.83 USD
-0.09 (-4.69%)
Last: 1/15/2026, 6:25:19 PM
1.85 USD
+0.02 (+1.09%)
After Hours: 1/15/2026, 6:25:19 PM

NAUT Key Statistics, Chart & Performance

Key Statistics
Market Cap231.15M
Revenue(TTM)N/A
Net Income(TTM)-62.81M
Shares126.31M
Float71.18M
52 Week High2.54
52 Week Low0.62
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.5
PEN/A
Fwd PEN/A
Earnings (Next)02-25
IPO2020-08-07
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
NAUT short term performance overview.The bars show the price performance of NAUT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

NAUT long term performance overview.The bars show the price performance of NAUT in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of NAUT is 1.83 USD. In the past month the price increased by 1.1%. In the past year, price decreased by -5.18%.

NAUTILUS BIOTECHNOLOGY INC / NAUT Daily stock chart

NAUT Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to NAUT. When comparing the yearly performance of all stocks, NAUT is one of the better performing stocks in the market, outperforming 90.82% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NAUT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NAUT. While NAUT has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NAUT Financial Highlights

Over the last trailing twelve months NAUT reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 10.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.26%
ROE -37.14%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%15.38%
Sales Q2Q%N/A
EPS 1Y (TTM)10.71%
Revenue 1Y (TTM)N/A

NAUT Forecast & Estimates

8 analysts have analysed NAUT and the average price target is 2.55 USD. This implies a price increase of 39.34% is expected in the next year compared to the current price of 1.83.


Analysts
Analysts85
Price Target2.55 (39.34%)
EPS Next Y8.93%
Revenue Next YearN/A

NAUT Ownership

Ownership
Inst Owners33.71%
Ins Owners32.36%
Short Float %0.55%
Short Ratio0.78

NAUT Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 27.89 234.69B
DHR DANAHER CORP 31.11 169.45B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 190.03 57.75B
A AGILENT TECHNOLOGIES INC 25.96 41.06B
IQV IQVIA HOLDINGS INC 20.75 41.09B
MTD METTLER-TOLEDO INTERNATIONAL 35.77 30.58B
WAT WATERS CORP 31.07 23.49B
ILMN ILLUMINA INC 33.33 22.20B
WST WEST PHARMACEUTICAL SERVICES 39.52 20.10B
MEDP MEDPACE HOLDINGS INC 43.22 17.41B
RVTY REVVITY INC 24.08 13.08B
TEM TEMPUS AI INC N/A 12.26B

Related stock screener links

About NAUT

Company Profile

NAUT logo image Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 124 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Company Info

NAUTILUS BIOTECHNOLOGY INC

2701 Eastlake Ave East

Seattle WASHINGTON US

CEO: Adam Stone

Employees: 124

NAUT Company Website

NAUT Investor Relations

Phone: 12063332001

NAUTILUS BIOTECHNOLOGY INC / NAUT FAQ

What does NAUT do?

Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 124 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.


What is the current price of NAUT stock?

The current stock price of NAUT is 1.83 USD. The price decreased by -4.69% in the last trading session.


Does NAUTILUS BIOTECHNOLOGY INC pay dividends?

NAUT does not pay a dividend.


How is the ChartMill rating for NAUTILUS BIOTECHNOLOGY INC?

NAUT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for NAUTILUS BIOTECHNOLOGY INC?

NAUTILUS BIOTECHNOLOGY INC (NAUT) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Would investing in NAUTILUS BIOTECHNOLOGY INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NAUT.


How many employees does NAUTILUS BIOTECHNOLOGY INC have?

NAUTILUS BIOTECHNOLOGY INC (NAUT) currently has 124 employees.